Glassman Wealth Services’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Glassman Wealth Services’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-20	Closed	-$1K	–	2079
2022 Q2	$1K	Buy	+20	New	+$597	﹤0.01%	1603
2021 Q4	–	Sell	-65	Closed	-$7K	–	1994
2021 Q3	$7K	Sell	65 -101	-61%	-$11.8K	﹤0.01%	883
2021 Q2	$23K	Buy	166 +50	+43%	+$5.65K	﹤0.01%	541
2021 Q1	$12K	Sell	116 -16	-12%	-$1.87K	﹤0.01%	681
2020 Q4	$16K	Buy	132 +13	+11%	+$1.71K	﹤0.01%	602
2020 Q3	$12K	Buy	+119	New	+$14.9K	﹤0.01%	582
2019 Q3	–	Sell	-3	Closed	–	–	1457
2019 Q2	$0	Buy	+3	New	+$259	﹤0.01%	1448

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glassman Wealth Services's RETA Position: Q3 2022 in Review

Glassman Wealth Services sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2022, closing a stake of 20 shares — an estimated $1K sold.

Glassman Wealth Services first reported a position in RETA in Q2 2019 and held it in 7 quarters. The position peaked at $23K in Q2 2021. 159 funds tracked by Wall St. Rank hold RETA as of Q3 2022.

Glassman Wealth Services reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
Glassman Wealth Services sold 20 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2022, an estimated $1K.
Glassman Wealth Services first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and held it in 7 quarters.
Glassman Wealth Services's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $23K in Q2 2021.
159 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2022.

Based on Glassman Wealth Services's 13F filing for Q3 2022, filed 9 Nov 2022.